Troy A. Ignelzi's Net Worth

$24.1 Million

Estimate Recalculated Nov 8, 2024 09:41PM EST

Who is Troy A. Ignelzi

Troy A. Ignelzi has an estimated net worth of $24.1 Million. This is based on reported shares across multiple companies, which include Karuna Therapeutics, Inc., Esperion Therapeutics, Inc., , scPharmaceuticals Inc., Contineum Therapeutics, Inc., and Rapport Therapeutics, Inc..

SEC CIK

Troy A. Ignelzi's CIK is 0001579829

Past Insider Trading and Trends

2021 was Troy A. Ignelzi's most active year for acquiring shares with 16 total transactions. Troy A. Ignelzi's most active month to acquire stocks was the month of January. 2020 was Troy A. Ignelzi's most active year for disposing of shares, totalling 28 transactions. Troy A. Ignelzi's most active month to dispose stocks was the month of August. 2022 saw Troy A. Ignelzi paying a total of $465,621.20 for 99,111 shares, this is the most they've acquired in one year. In 2022 Troy A. Ignelzi cashed out on 104,355 shares for a total of $11,653,532.91, their largest year based on trade value.

Loading...

Attention insiders:Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

Karuna Therapeutics, Inc.

Chief Financial Officer
Updated Aug 24, 2023
Form 4
-1.20%
-1.50K
$92.16
-$248.88K
Aug 24, 2023
123.71K
Sale
Aug 22
Form 4
-6.71%
-9.00K
$116.31
-$1.93M
May 25, 2023
125.21K
Sale
May 23
Form 4
-4.28%
-6.00K
$99.60
-$1.08M
Feb 23, 2023
134.21K
Sale
ScheduledFeb 21
Form 4
119.06%
26.00K
Feb 13, 2023
47.84K
Grant
Feb 09
Form 4
-0.77%
-1.02K
$105.18
-$195.22K
Jan 19, 2023
131.56K
Sale
ScheduledJan 17 - Jan 18
Form 4
$9.20
$109.18K
Dec 19, 2022
141.77K
Options
Dec 16
Form 4
-11.14%
-16.50K
$117.53
-$3.57M
Nov 17, 2022
131.58K
Sale
ScheduledNov 15
Form 4
-60.07%
-15.00K
$229.61
-$3.44M
Oct 04, 2022
9.97K
Sale
Sep 30 - Oct 04
Form 4
-9.19%
-16.50K
$118.52
-$3.61M
Aug 11, 2022
163.08K
Sale
ScheduledAug 09
Form 4
-2.31%
-4.24K
$70.22
-$517.94K
Apr 21, 2022
179.58K
Sale
ScheduledApr 19 - Apr 21
Form 4
25.36%
47.00K
$60.17
-$152.91K
Feb 17, 2022
232.33K
Sell-Options
ScheduledFeb 15 - Feb 16
Form 4
$9.20
$64.12K
Dec 22, 2021
194.26K
Options
Dec 21
Form 4
-6.83%
-13.50K
$80.76
-$1.93M
Nov 10, 2021
184.23K
Sale
ScheduledNov 08
Form 4
-4.81%
-10.00K
$63.29
-$1.08M
Sep 10, 2021
197.73K
Sale
ScheduledSep 08 - Sep 10
Form 4
$9.20
$46.00K
Aug 23, 2021
207.73K
Options
Aug 20
Form 4
-12.60%
-3.50K
$69.66
-$423.27K
Jun 16, 2021
24.28K
Sale
Jun 14 - Jun 16
Form 4
-3.35%
-7.20K
$59.78
-$728.25K
May 12, 2021
207.73K
Sale
ScheduledMay 10 - May 12
Form 4
51.65K
Feb 24, 2021
51.65K
Grant
Feb 23
Form 4
-4.45%
-10.00K
$64.38
-$1.10M
Feb 17, 2021
214.93K
Sale
ScheduledFeb 16
Form 4
-3.43%
-8.00K
$56.85
-$762.32K
Jan 12, 2021
224.93K
Sale
ScheduledJan 08
Form 4
$9.20
$73.60K
Dec 29, 2020
245.20K
Options
Dec 29
Form 4
-4.15%
-10.00K
$57.41
-$964.05K
Nov 10, 2020
230.79K
Sale
ScheduledNov 06 - Nov 10
Form 4
-0.82%
-2.00K
$41.25
-$128.20K
Sep 10, 2020
240.79K
Sale
ScheduledSep 08
Form 4
$9.20
$46.00K
Aug 27, 2020
242.79K
Options
Aug 25
Form 4
-3.19%
-8.00K
$53.97
-$716.32K
Jul 10, 2020
242.79K
Sale
ScheduledJul 08
Form 4
-3.09%
-8.00K
$50.76
-$664.88K
Jun 17, 2020
250.79K
Sale
ScheduledJun 15 - Jun 16
Form 4
-2.82%
-7.50K
$46.29
-$556.35K
May 12, 2020
258.79K
Sale
ScheduledMay 08
Form 4
-2.74%
-7.50K
$47.85
-$579.75K
Mar 04, 2020
266.29K
Sale
ScheduledMar 02
Form 4
-50.00%
-55.00K
Feb 19, 2020
55.00K
Grant
Feb 14
Form 3
Jun 27, 2019
Showing 30 results

Esperion Therapeutics, Inc.

Vice President
Updated Jun 25, 2013
Form 3
Jun 25, 2013
Showing 1 results

Investor
Updated Feb 24, 2023
Form 4
-100.00%
-95.15K
Feb 24, 2023
Disposition
Feb 24
Form 3
Jan 06, 2022
Showing 2 results

scPharmaceuticals Inc.

Chief Financial Officer
Updated Jan 19, 2018
Form 4
42.62K
Jan 19, 2018
42.62K
Grant
Jan 17
Form 3
Nov 16, 2017
Showing 2 results

Contineum Therapeutics, Inc.

Investor
Updated May 29, 2024
Form 4
6.35K
May 29, 2024
6.35K
Grant
May 24
Form 3
May 20, 2024
Form 4
23.15K
May 20, 2024
23.15K
Grant
May 20
Showing 3 results

Rapport Therapeutics, Inc.

Chief Financial Officer
Updated Jun 10, 2024
Form 4
81.37K
Jun 10, 2024
81.37K
Grant
Jun 06
Form 3
Jun 06, 2024
Showing 2 results